netFormulary Chelsea and Westminster Hospital NHS
NHS Foundation Trust  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
Panobinostat  (Farydak®)
View adult BNF
Formulary
NICE Formulary
High Cost Medicine
Panobinostat (Farydak®) 10mg hard capsules
Panobinostat (Farydak®) 15mg hard capsules
Panobinostat (Farydak®) 20mg hard capsules
For use in line with NICE TA380 (Panobinostat for treating multiple myeloma after at least 2 previous treatments) 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Cytotoxic Drug Atezolizumab (Tecentriq®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Cancer Drugs Fund

Atezolizumab (Tecentriq®) 1200mg concentrate for solution for infusion

To be used in line with NICE TA492 (Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable)

To be used in line with NICE TA 525 (Atezolizumab for untreated locally advanced or metastatic urothelial carcinoma after platimum-containing chemotherapy)

To be used in line with NICE TA 520 (Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy)

To be used in line with NICE TA 584 (Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer)

 
   
Axitinib (Inlyta®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Axitinib (Inlyta®) 1mg tablet
For use in line with NICE TA333 (Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment)  
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Bosutinib (Bosulif®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Bosutinib (Bosulif®) 100mg tablet
Bosutinib (Bosulif®) 500mg tablet
For use in line with NICE TA401 (Bosutinib for previously treated chronic myeloid leukaemia)
 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Cytotoxic Drug Carfilzomib (Kyprolis®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Carfilzomib 2mg/ml injection
For use in line with NICE TA457 (Carfilzomib for previously treated multiple myeloma) 
   
Cytotoxic Drug Ceritinib (Zykadia®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine

Ceritinib 150mg capsules (Zykadia®)
For use in line with NICE TA395 (Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer)

For use in line with NICE TA500 (Ceritinib for untreated ALK-positive non-small-cell lung cancer)

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
   
Dabrafenib (Tafinlar®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Dabrafenib (Tafinlar®) 50mg capsule
Dabrafenib (Tafinlar®) 75mg capsule
Use in line with NICE TA321 (Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma)
 
Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
   
Durvalumab (Imfinzi®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine

Durvalumab (Imfinzi®) 50mg/ml concentrate for solution for infusion 

 

For use in line with NICE TA578 (Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation)

 
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Eribulin (Halaven®) 0.88mg/2ml injection
Eribulin (Halaven®) 1.32mg/3ml injection
For use in line with NICE TA250 (Eribulin for the treatment of locally advanced or metastatic breast cancer)
For use in line with NICE TA423 (Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens)
 
Link  NICE TA250: Breast cancer (advanced) - eribulin
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
   
Ibrutinib (Imbruvica®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Ibrutinib (Imbruvica®) 140mg hard capsules
For use in line with NICE TA429 (Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation)


For use in line with NICE TA491 (Ibrutinib for treating Waldernstrom's macroglobulinaemia) 
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
   
Idelalisib (Zydelig®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Cancer Drugs Fund
Idelalisib (Zydelig®) 100mg tablet
Idelalisib (Zydelig®) 150mg tablet
For use in line with NICE TA359 (Idelalisib for treating chronic lymphocytic leukaemia) 
Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
   
Lenvatinib (Kisplyx®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine

Lenvatinib 4mg capsule

Lenvatinib 10mg capsule

For use in line with NICE TA498 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma 

 
   
Nintedanib
View adult BNF View childrens BNF
Formulary
NICE Formulary
Nintedanib 100mg capsule
Nintedanib 150mg capsule
For use in line with NICE TA347 (Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer) 
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Osimertinib (Tagrisso®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Osimertinib 40mg tablet
Osimertinib 80mg tablet
For use in line with NICE TA416 (Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer) 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
   
Palbociclib (Ibrance®)
View adult BNF View childrens BNF
Formulary
NICE Formulary

Palbociclib (Ibrance®) 75mg tablets
Palbociclib (Ibrance®) 100mg tablets
Palbociclib (Ibrance®) 125mg tablets
For use in line with NICE TA495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

 
   
Pembrolizumab (Keytruda®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine

Pembrolizumab (Keytruda®) 50mg injection

For use in line with NICE TA357 (Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab)
For use in line with NICE TA366 (Pembrolizumab for advanced melanoma not previously treated with ipilimumab)
For use in line with NICE TA428 (Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy)
For use in line with NICE TA447 (Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer)

For use in line with NICE TA519 (Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy)

For use in line with NICE TA522 (Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable)

For use in line with NICE TA531 (Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer)

For use in line with NICE TA553 (Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence)

For use in line with NICE TA557 (Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer)

 
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
   
Ponatinib (Iclusig®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Ponatinib (Iclusig®) 15mg tablet
Ponatinib (Iclusig®) 45mg tablet
For use in line with NICE TA451 (Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia) 
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Ribociclib tablets (Kisqali®)
View adult BNF View childrens BNF
Formulary
NICE Formulary

Ribociclib (Kisqali®) 200mg tablets
For use in line with NICE TA 495 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

 
   
Ruxolitinib (Jakavi®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Ruxolitinib (Jakavi®) 5mg tablet
Ruxolitinib (Jakavi®) 15mg tablet
Ruxolitinib (Jakavi®) 20mg tablet
For use in line with NICE TA386 (Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis) 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Trametinib (Mekinist®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Trametinib 0.5mg film coated tablets (Mekinist®)
Trametinib 2.0mg film coated tablets (Mekinist®)
For use in line with NICE TA396 (Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma)
 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
   
Trifluridine-tipiracil (Lonsurf®)
View adult BNF View childrens BNF
Formulary
On Formulary
Trifluridine-tipiracil 15 mg/6.14 mg film-coated tablets (Lonsurf®)
Trifluridine-tipiracil 20 mg/8.19 mg film-coated tablets (Lonsurf®)
For use in line with NICE TA405 (Trifluridine–tipiracil for previously treated metastatic colorectal cancer)

 
Link  NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
   
Cytotoxic Drug Venetoclax (Venclyxto®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Cancer Drugs Fund

Venetoclax (Venclyxto®) 10mg film-coated tablets

Venetoclax (Venclyxto®) 50mg film-coated tablets

Venetoclax (Venclyxto®) 100mg film-coated tablets

 

To be used in line with NICE TA487 (Venetoclax for treating chronic lymphocytic leukaemia)

To be used in line with NICE TA562 (Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia)

 
   
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
Bevacizumab (Avastin®)
(Oncology)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Bevacizumab (Avastin®) 1.25mg intra-ocular injection
Bevacizumab (Avastin®) 100mg infusion
Bevacizumab (Avastin®) 400mg infusion
For use in line with NICE TA212 (Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer)
For use in line with NICE TA214 (Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer)
For use in line with NICE TA242 (Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy)
For use in line with NICE TA263 (Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer)
For use in line with NICE TA284 (Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer)
For use in line with NICE TA285 (Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer)


 
Link  NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA263: Breast cancer with capecitabine
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
   
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Bortezomib (Velcade®) 3.5mg injection
For use in line with NICE TA129 (Bortezomib monotherapy for relapsed multiple myeloma)
For use in line with NICE TA228 (Bortezomib and thalidomide for the first‑line treatment of multiple myeloma)
For use in line with NICE TA311 (Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation)

For use in line with NICE TA370 (Bortezomib for previously untreated mantle cell lymphoma)
 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Link  NICE TA311: Multiple myeloma - bortezomib (induction therapy
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin (Adcetris®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund

Brentuximab (Adcetris®)vedotin 50mg injection
For use in line with NICE TA446 (Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma)
For use in line with NICE TA478 (Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma)

For use in line with NICE TA524 (Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma)

For use in line with NICE TA577 (Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma)

 
   
08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Cetuximab(Erbitux®) 5mg/ml injection
For use in line with NICE TA 176 (Cetuximab for the first-line treatment of metastatic colorectal cancer)
For use in line with NICE TA439 (Cetuximab and panitumumab for previously untreated metastatic colorectal cancer)
For use in line with NICE TA473 (Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck 
Link  NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Link  NICE TA176: Colorectal cancer (first line) - cetuximab
Link  NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Cytotoxic Drug Dacarbazine
View adult BNF View childrens BNF
Formulary
On Formulary
Dacarbazine 100mg injection
Dacarbazine 120mg injection
Dacarbazine 500mg injection
 
   
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View childrens BNF
Formulary
On Formulary
Hydroxycarbamide 500mg capsule 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab (Yervoy®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Ipilimumab(Yervoy®) 5mg/ml infusion
For use in line with NICE TA268 (Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma)
For use in line with NICE TA319 (Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma)
 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
   
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
View adult BNF View childrens BNF
Formulary
On Formulary
Pentostatin (Nipent®) 10mg injection 
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View childrens BNF
Formulary
On Formulary
Carboplatin 50mg injection
Carboplatin 150mg injection
Carboplatin 450mg injection
Carboplatin 600mg injection 
   
Cytotoxic Drug Cisplatin
View adult BNF View childrens BNF
Formulary
On Formulary
Cisplatin 10mg injection
Cisplatin 50mg injection
Cisplatin 100mg injection 
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
Cytotoxic Drug Procarbazine
View adult BNF View childrens BNF
Formulary
On Formulary
Procarbazine 50mg capsule 
   
08.01.05  Expand sub section  Protein kinase inhibitors
Cytotoxic Drug Abemaclib ( Verzenios®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine

Abemaclib (Verzenios®) 50mg film coated tablets

Abemaclib (Verzenios®) 100mg film coated tablets

Abemaclib (Verzenios®) 150mg film coated tablets

For use in line with NICE TA563: Abemaciclib with an aromatase inhibitor for previously, untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

 
   
Afatinib (Giotrif®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine
Afatinib (Giotrif®) 20mg tablet
Afatinib (Giotrif®) 30mg tablet
Afatinib (Giotrif®) 40mg tablet
Afatinib (Giotrif®) 50mg tablet
For use in line with NICE TA310 (Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer)
 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Alectinib (Alecensa®)
View adult BNF View childrens BNF
Formulary
On Formulary

Alectinib (Alecensa®) 150mg capsules

 

For use in line with NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

 
   
Cytotoxic Drug Brigatinib (Alunbrig®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine

Brigatinib (Alunbrig®) 30mg film coated tablets

Brigatinib (Alunbrig®) 90mg film coated tablets

Brigatinib (Alunbrig®) 180mg film coated tablets

For use in line with NICE TA 571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

 
   
Cytotoxic Drug Cabozantinib (Cometriq®)
View adult BNF View childrens BNF
Formulary
NICE Approved
High Cost Medicine
Cancer Drugs Fund
Cabozantinib
For use in line with NICE TA463 (Cabozantinib for previously treated advanced renal cell carcinoma) 
   
Crizotinib (Xalkori®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund

Crizotinib (Xalkori®) 200mg capsule
Crizotinib (Xalkori®) 250mg capsule
For use in line with NICE TA406 (Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer)
For use in line with NICE TA422 (Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer)

For use in line with NICE TA529 (Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer)

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
   
Dasatinib (Sprycel®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Dasatinib (Sprycel®) 20mg tablet
Dasatinib (Sprycel®) 50mg tablet
Dasatinib (Sprycel®) 70mg tablet
Dasatinib (Sprycel®) 100mg tablet
For use in line with NICE TA241 (Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance)

For use in line with NICE TA251 (Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia)
For use in line with NICE TA425 (Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia)
For use in line with NICE TA426 (Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia)

 
Link  NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Erlotinib (Tarceva®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Erlotinib (Tarceva®) 25mg tablet
Erlotinib (Tarceva®) 100mg tablet
Erlotinib (Tarceva®) 150mg tablet
For use in line with NICE TA374 (Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy)
For use in line with NICE TA227 (Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer)
For use line with NICE TA256 (Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation)
 
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Link  NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Link  NICE TA374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Everolimus (Votubia®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Everolimus (Votubia®) 2.5mg tablet
Everolimus (Votubia®) 5mg tablet
Everolimus (Votubia®) 10mg tablet
For use in line with NICE TA348 (Everolimus for preventing organ rejection in liver transplantation)
For use in line with NICE TA421 (Everolimus with exemestane for treating advanced breast cancer after endocrine therapy)
For use in line with NICE TA449 (Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease)
 
Link  NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib (Iressa®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Gefitinib (Iressa®) 250mg tablet
For use in line with NICE TA374 (Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy)
For use in line with NICE TA192 (Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer)  
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Imatinib (Gilvec®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Imatinib (Gilvec®) 100mg tablet
Imatinib (Gilvec®) 400mg tablet
For use in line with NICE TA70 (Guidance on the use of imatinib for chronic myeloid leuakaemia)
For use in line with NICE TA209 (Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours)
For use in line with NICE TA (Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance)
For ues in line with NICE TA (Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia)
For use in line with NICE TA326 (Imatinib for the adjuvant treatment of gastrointestinal stromal tumours)
For us in line with NICE TA86 (Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours)
For use in line with NICE TA425 (Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia)
For use in line with NICE TA426 (Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia)
 
Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Link  NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Leukaemia (chronic myeloid) - imatinib
Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
   
Lapatinib (Tyverb®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Lapatinib (Tyverb®) 250mg tablet
For use in line with NICE TA257(Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2)
 
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
   
Nilotinib (Tasigna®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Nilotinib (Tasigna®) 200mg capsule
For use in line with NICE TA241 (Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance)
For use in line with NICE TA251 (Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia)
For use in line with NICE TA425 (Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia)
For use in line with NICE TA426 (Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia)
 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Pazopanib (Votrient®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Pazopanib (Votrient®) 200mg tablet
Pazopanib (Votrient®) 400mg tablet
For use in line with NICE TA215 (Pazopanib for the first-line treatment of advanced renal cell carcinoma)
 
Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
   
Sunitinib
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine
Cancer Drugs Fund

Sunitinib (Sutent®) 12.5mg capsule
Sunitinib (Sutent®) 25mg capsule

Sunitinib 37.5 mg capsules

Sunitinib 50 mg capsules

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
   
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine
Cancer Drugs Fund
Temsirolimus (Torisel®) 30mg infusion 
Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
   
Vemurafenib (Zelboraf®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Vemurafenib (Zelboraf®)240mg tablet
For use in line with NICE TA269 (Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma)  
Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund
Cabazitaxel (Jevtana®) 40mg/ml infusion
For use in line with NICE guidance TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
 
Link  NICE TA255: Cabazitaxel for prostate cancer
   
Cytotoxic Drug Docetaxel
View adult BNF View childrens BNF
Formulary
NICE Formulary
Docetaxel 40mg/ml injection
For use in line with NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
   
Paclitaxel
View adult BNF View childrens BNF
Formulary
NICE Formulary
Paclitaxel 30mg injection
Paclitaxel 100mg injection
For use in line with NICE TA55 (Guidance on the use of paclitaxel in the treatment of ovarian cancer)
For use in line with NICE TA360 (Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer)
 
Link  NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Cancer Drugs Fund

Pertuzumab (Perjeta®) 420mg/14ml injection


For use in line with NICE TA424 (Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer)

For use in line with NICE TA569 (Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer)

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
   
Cytotoxic Drug Trastuzumab (Herceptin®)
View adult BNF View childrens BNF
Formulary
NICE Formulary
Trastuzumab(Herceptin®)600mg/5ml injection
For use in line with NICE TA107 (Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer)
For use in line with NICE TA208 (Trastuzumab for the treatment of HER2-positive metastatic gastric cancer)
For use in line with NICE TA257 (Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER)
For use in line with NICE TA34 (Guidance on the use of trastuzumab for the treatment of advanced breast cancer)  
Link  NICE TA107: Breast cancer (early) - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
   
Trastuzumab emtansine
View adult BNF View childrens BNF
Formulary
NICE Formulary
High Cost Medicine
Trastuzumab emtansine 100mg injection
Trastuzumab emtansine 160mg injection

For use in line with NICE TA371 (Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane)
For use in line with NICE TA458 (Tastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane 
Link  NICE TA371: Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
   
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
Cytotoxic Drug Vismodegib (Erivedge®)
View adult BNF View childrens BNF
Formulary
On Formulary
High Cost Medicine
Cancer Drugs Fund
Vismodegib (Erivedge®) 150mg capsule 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

On Formulary

Formulary  

NICE Formulary

Nice Approved / Formulary  

NICE Approved

NICE approved  

Amber Restricted

Amber Restricted Use  

Non Formulary

Non Formulary  

netFormulary